CD163 and glioma: As listed in Table 1, REST was significantly positively correlated with B cell’s biomarkers (CD19 and CD79A), CD4+ immune cell’s biomarker (CD4), M1 macrophage’s biomarkers (IRF5 and PTGS2), M2 macrophage’s biomarkers (CD163, VSIG4, and MS4A4A), neutrophil’s biomarkers (ITGAM), and dendritic cell’ s biomarkers (HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DPA1, CD1C, NRP1, and ITGAX) in glioma.